Bermuda-based clinical-stage pharmaceutical company Axovant Sciences has priced its underwritten public offering of 30 million of its common shares at $1 per share.
Axovant expects gross proceeds from the offering to be roughly $30 million before deducting underwriting discounts and commissions.
The company has granted the underwriters a 30-day option to acquire up to a further 4.5 million of its common shares on the same terms and conditions.
The underwritten public offering is expected to be completed on December 18, 2018, subject to customary closing conditions.